Australian CRO Novotech extends operations to India through JV with ETI Klinical

Australian clinical research company Novotech entered into a strategic partnership pact with ETI Klinical Pvt Ltd of India.

The Novotech-ETI Klinical joint venture targets to serve the growing demand for global clinical research in the region. The companies will operate across India and offer full clinical and data management services.

Karle Group CEO Mr Mahendra Karle said that with the joint venture clients could access the company’s extensive reach across India which included Memorandum of Understanding with 92 pre-qualified sites with proven recruitment capability and compliance, providing access to over 5 million patients and 13,000 beds.

The therapeutic areas in which the Novotech-ETI Klinical joint venture operates include oncology, gastroenterology, urology, nephrology, ophthalmology, cardiology, diabetology, dermatology, orthopedics, postoperative pain, neurology, otorhinolaryngology, infectious diseases, respiratory diseases, endocrinology, psychiatry, geriatrics, hematology, metabolic disorders devices and vaccines.

The Novotech-ETI Klinical joint venture will leverage the huge opportunities in the growing Indian clinical research sector and drive more global studies to the country, Novotech CEO Alek Safarian said.

The two companies have extensive experience managing FDA clinical research and will collaborate to service both regional and international pharma and biotech firms.

“We approached Novotech because of its proven reputation in the region, its focus on Australasia, and its global business development reach and client network.” said Mr. Mahendra Karle.

The joint venture data management services include Oracle Clinical and SAS, and Novotech’s Clintrial giving maximum flexibility to clients.

ETI offers a mix of clinical research services, real-time data acquisition and personalized communication processes to manage a clinical trial from initial planning to approval, on time and on budget.

“We share a similar business culture and approach to high-quality and time critical clinical trials and research, serving the pharmaceutical, biotechnology, and medical device industries,” said Safarian.

Last month, the Indian CRO GVK Biosciences (GVK Bio) and Chinese Excel PharmaStudies (Excel) have joined hands to offer clinical trial sevices in Asian region – a first-ever alliance between a Chinese and Indian CRO.

The GVK – Bio Excel alliance expected to synergise the strengths of each company and offer clients with services that span India and China. Under the terms of the arrangement, GVK BIO and Excel will help sponsors conduct and manage Phase II-IV clinical trials, statistical analysis and medical writing. Any India trial for Excel will be carried out by the GVK BIO clinical research team and will be managed by a core project management team of Excel. Similarly, a GVK BIO China trial will be carried out by the Excel team and managed by GVK BIO’s project management team.

Headquartered in Sydney, Novotech is focused on the Australasian region but has worldwide reach through the company’s network of strategic partners. As the largest independent CRO in Australia, Novotech offers a level of flexibility and local knowledge that is unmatched among other contract research organizations in the region.Novotech has been recognized as Australia’s leading CRO by Frost & Sullivan for the past two years.

ETI Karle Clinical Pvt. Ltd belongs to the Karle Group of Companies, a US $ 600 million Indian Multinational. ETI offers a mix of clinical research services, real-time data acquisition and personalized communication processes to manage a clinical trial from initial planning to approval.